Genentech Announces the Launch of New Safety Website
On June 7th, 2018, Genentech announced a new web portal for patients and caregivers intended to provide timely and accurate information on targeted serious adverse events of interest for HEMLIBRA. Earlier this year, Genentech launched a similar site specifically for healthcare providers.
In announcing the launch, Genentech stated “This website is meant to serve as just one of the ways we will provide updated, verified safety information to the hemophilia community, specifically about thrombotic microangiopathy, serious thrombotic events (blood clots), and fatalities in patients taking emicizumab-kxwh, whether or not such events are related to emicizumab-kxwh.”
NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.